Furmonertinib in Patients With Leptomeningeal Metastases Associated With EGFR Mutated NSCLC
Status:
Enrolling by invitation
Trial end date:
2025-08-31
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to evaluate the clinical efficacy and safety of
Furmonertinib in EGFR mutated NSCLC patients with leptomeningeal metastasis and to explore
the feasibility of CSF ctDNA detection for efficacy evaluation. Participants will be treated
with 160mg Furmonertinib daily and tumor evaluation will be performed every 6-8 weeks. The
participants' blood and cerebrospinal fluid samples will be collected three times during the
study for ctDNA detection.